Pulmonary Sarcoidosis Lung Function Medication Request More Information Trial Objective Researchers are trying to determine if an investigational medication called CMK389 improves lung function for people with chronic pulmonary sarcoidosis. The study also will determine if the drug is safe and well-tolerated in study participants. Enrollment Active Clinical Trials Currently Recruiting Who Can Participate People with pulmonary sarcoidosis who are on a stable treatment of prednisone for at least six months prior to starting the study. Age: 18-75 Gender: Any Gender Estimated Time Commitment 13 clinic visits lasting 4-8 hours each over 9 to 11 months × Payments are intended to compensate the participant for their time and effort during the study. Payments are typically given to the participant at the end of each completed study visit. Reimbursements are intended to compensate the participant for travel-related expenses. They must be approved by the study staff and require you to turn in receipts. Travel reimbursement will vary from study to study. Payment & Reimbursement Payment: Provided Travel Reimbursement: Available Trial Contact For more information, contact: Cindy Wainscoat 303.398.1259 Request More Information Trial Location National Jewish Main Campus, Denver, CO Trial Sponsors Novartis Pharmaceuticals Corporation Principal Investigators Clara Restrepo, MD + × Clara Restrepo, MD Associate Professor Director, Sleep Laboratory Division of Environmental & Occupational Health Sciences Department of Medicine View Full Profile Patient Rating 4.8 out of 5 stars Make an Appoinment Co-Investigators Lisa Maier, MD, MSPH, FCCP + × Lisa Maier, MD, MSPH, FCCP Professor Director, Division of Env & Occ Health Science Core Clinical Lab Chief, Division of Environmental & Occupational Health Sciences Department of Medicine View Full Profile Patient Rating 4.9 out of 5 stars Make an Appoinment Request More Information By completing this form, you agree to learn more about this study and see if you qualify. First Name:* Last Name:* Email Address:* Phone:* I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: YesNo
Trial Objective Researchers are trying to determine if an investigational medication called CMK389 improves lung function for people with chronic pulmonary sarcoidosis. The study also will determine if the drug is safe and well-tolerated in study participants.